<DOC>
	<DOCNO>NCT00327223</DOCNO>
	<brief_summary>AMP-011 Phase 1 study design extend understand toxicity pharmacology imexon investigate schedule daily treatment 5 day every three week . The objective study determine maximally tolerate dose , pharmacokinetics , toxicity drug designate schedule .</brief_summary>
	<brief_title>Safety Study Imexon Treatment Patients With Metastatic Disseminated Malignancy</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Previously treat malignant disease type . Prior treatment ; least one prior regimen require . Able perform activity daily live . Off prior cancer therapy least 4 week . If female , neither pregnant nursing . Willing use contraceptive prevent pregnancy . No serious illness . No active malignancy . No serious infection . No current drug therapy cancer . Blood count blood chemistry near normal range . Prior radiation permit . No active brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Metastatic cancer</keyword>
	<keyword>Disseminated malignant disease</keyword>
</DOC>